(AOF) – Valbiotis, an R&D company specializing in the prevention and fight against metabolic and cardiovascular diseases, announces the signature of a research partnership in the intestinal microbiota with the Medis Unit of Clermont Auvergne University on its active substances against dyslipidemia and metabolic damage to the liver. This work will make it possible to develop, by 2024, the most complete model of the human upper digestive tract in the world, integrating in particular the microbiota of the small intestine.
The research project, called MIMETiv, will be carried out by a joint laboratory, partly funded by the National Research Agency (ANR) to the tune of €363,000. It will provide exclusive data on the metabolites, bioavailability, mode of action at the intestinal level and effects on the human microbiota of these two active substances.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.